More major insurance companies covering Kerecis intact fish-skin grafts as new studies show big benefits for burns and diabetic foot ulcers

https://www.news-medical.net/news/20260903/More-major-insurance-companies-covering-Kerecis-intact-fish-skin-grafts-as-new-studies-show-big-benefits-for-burns-and-diabetic-foot-ulcers.aspx Kerecis, the company pioneering the use of sustainably sourced fish‑skin grafts in cellular therapy and tissue regeneration, has significantly expanded U.S. insurance coverage, adding more than 40 million covered lives through recent policy updates across multiple large national and regional insurers, as well as state Medicaid programs.

Too little or too much testosterone may matter for heart rhythm

Conflicting clinical trials and emerging mechanistic evidence are reshaping how researchers think about testosterone levels, replacement therapy, and the heart’s electrical rhythm. https://www.news-medical.net/news/20260902/Too-little-or-too-much-testosterone-may-matter-for-heart-rhythm.aspx In a recent review published in the Journal of the Endocrine Society, researchers investigated the effects of serum testosterone levels and testosterone replacement therapy (TRT) on the risk of atrial fibrillation (AF). The evidence was not consistent across studies, but several reports pointed to a higher AF risk at both low and high testosterone levels. This may be relevant when assessing AF risk in men receiving or considering TRT, although the association still needs to be confirmed in future studies.

Menopause may start changing the gut years before periods stop

https://www.news-medical.net/news/20260902/Menopause-may-start-changing-the-gut-years-before-periods-stop.aspx Blood biomarkers began shifting years before the final menstrual period, revealing a prolonged biological change that may connect the menopausal transition with inflammation. A recent study published in the Journal of Clinical Investigation found that the menopause transition was associated with a sustained increase in blood markers of compromised gut epithelial barrier integrity.

Blood-based CRC screening: closer, but not there yet The Lancet Gastroenterology & Hepatology ++... ++

Blood-based CRC screening: closer, but not there yet The Lancet Gastroenterology & Hepatology https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00244-X/fulltext?dgcid=raven_jbs_etoc_email Oct 2026 Volume 11Number 10p863-942, e11 https://www.thelancet.com/journals/langas/issue/vol11no10/PIIS2468-1253(26)X2008-8 A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study Alessandro Mannucci, MDa,b ∙ Caiming Xu, MDa ∙ Prof Francesc Balaguer, MDd ∙ Prof Yoshinaga Okugawa, MDe ∙ Prof Yuji Toiyama, MDe ∙ Prof Miguel Pera, MDf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00180-9/abstract?dgcid=raven_jbs_etoc_feature_langas The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial Prof Mazen Noureddin, MDa,b,c,d Send email to noureddinmd@pinnacleresearch.com ∙ Prof Winston Dunn, MDc,e ∙ Rashmee Patil, MDc ∙ Dimple Desai, MDc ∙ Rohit Puskoor, MDc ∙ Jaehee Shin, MSf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00130-5/abstract?dgcid=raven_jbs_etoc_feature_langas

Ménière's disease: the treatment evidence we still do not have The Lancet Regional Health – Europe ++... ++

Ménière's disease: the treatment evidence we still do not have The Lancet Regional Health – Europe https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00265-6/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 68 https://www.thelancet.com/journals/lanepe/issue/vol68nonull/PIIS2666-7762(26)X2005-1 Whole genome sequencing in cerebral palsy: a UK paediatric pilot study Thiloka E. Ratnaikea,b,c,q ∙ Heather H. Piercea,q ∙ Alison J. Coffeyd,q ∙ Joao M.L. Diasa ∙ Iain R.L. Keana ∙ Emily Lia,e ∙ et al. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00198-5/fulltext?dgcid=raven_jbs_etoc_feature_lanepe Effectiveness of the hope groups intervention on mental health, parenting practices, and violence against children among Ukrainian parents and caregivers affected by war and displacement: a cluster randomised controlled trial Sydney Tuckera,r Send email to sydney.tucker@spi.ox.ac.uk ∙ Nicole Baldonadob ∙ Olha H. Ruinac ∙ G.J. Melendez-Torresd ∙ Seth Flaxmane ∙ Lyudmila Brynf ∙ et al. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00195-X/fulltext?dgcid=raven_jbs_etoc_feature_lanepe

A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD

A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-microglial-transition-could-mean-the-difference-between-a-healthy-brain-and-alzheimer-s-disease-17273?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_8bGf4hEcj4mSOC2nyrCHQ02MkhdavUWOzYbd_L5dxNV31U4IP3PIkJkX5nEDjs22_r4-ZaQdJyXPCsRDhzAWkrT5KTA&_hsmi=437313448&utm_content=437313448&utm_source=hs_email Whether or not someone develops Alzheimer’s disease could be the result of a key transition in microglial activity, according to new research published recently in Nature Medicine. Researchers led by Mark Fiers and Bart De Strooper at the VIB-KU Leuven Center for Neuroscience and University College London, in collaboration with Muna Therapeutics, found that microglia switch from an early inflammatory response in the presence of amyloid plaques to an antigen-presenting state that coincides with the development of tau tangles.

Turning tumor macrophages from foes into allies A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance. Written byBree Foster, PhD

Turning tumor macrophages from foes into allies A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance. Written byBree Foster, PhD https://www.drugdiscoverynews.com/turning-tumor-macrophages-from-foes-into-allies-16970?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8LeGIDqwQK0NXX4KDdOlxINggt0GfNrz_owZfQCXrWO1YXHur8samsS9eRBEDcmXaGmtyC7oSMAMRDrgtFiaZvIYGXIw&_hsmi=437313448&utm_content=437313448&utm_source=hs_email Cancer immunotherapy has transformed oncology by harnessing the immune system to recognize and destroy tumors. Approaches such as immune checkpoint inhibitors and engineered immune cells have delivered durable responses in some patients — and nowhere more dramatically than CAR-T cell therapies in blood cancers. Several CAR-T treatments are now FDA-approved and have produced long-term remissions in leukemia and lymphoma.